Table 2 Characteristics of the study population

Age [years]

65.60 ± 10.30

67.10 ± 8.46

0.115

Male [cases (%)]

259 (70.96)

91 (60.26)

0.018

BMI (kg/m²)

24.29 ± 3.00

24.24 ± 3.38

0.878

Systolic pressure (mmHg)

126.13 ± 13.73

128.38 ± 15.18

0.116

Diastolic pressure (mmHg)

68.92 ± 10.16

69.03 ± 9.69

0.911

Former smokers [cases (%)]

175 (47.95)

63 (41.72)

0.197

Current smokers [cases (%)]

26 (7.12)

8 (5.30)

0.447

Hypertension history [cases (%)]

270 (73.97)

120 (79.47)

0.186

Diabetes history [cases (%)]

119 (32.60)

55 (36.42)

0.404

Family history [cases (%)]

32 (8.77)

10 (6.62)

0.418

Creatinine (μmoI/L)

86.99 ± 16.71

90.77 ± 22.01

0.034

hs-CRP (mg/L)

3.00 (1.00–5.00)

3 (1.00–6.00)

0.252

Single-vessel lesions [cases (%)]*

111 (30.41)

39 (25.83)

0.243

Double-vessel lesions [cases (%)]

112 (30.68)

39 (25.83)

0.219

Triple-vessel lesions [cases (%)]

142 (38.90)

73 (48.34)

0.048

Left main lesions [cases (%)]

36 (9.86)

15 (9.93)

0.980

Total coronary occlusion [cases (%)]

63 (17.26)

40 (26.49)

0.017

Coronary stents (number)

2.41 ± 1.59

2.64 ± 1.61

0.132

Baseline lipids levels

TC (mmol/L)

4.24 ± 1.18

4.60 ± 1.08

0.001

LDL-C (mmol/L)

2.43 ± 0.97

2.68 ± 0.84

0.003

HDL-C (mmol/L)

1.05 ± 0.27

1.14 ± 0.29

0.001

Lp(a) (mg/dL)

10.0 (7.0–14.0)

42.0 (28.0–74.0)

< 0.001

Triglyceride (mmol/L)

1.62 ± 1.01

1.71 ± 1.69

0.569

Lipids levels at 1-month follow-up

TC (mmol/L)

3.23 ± 0.71

3.48 ± 0.65

< 0.001

LDL-C (mmol/L)

1.60 ± 0.55

1.75 ± 0.50

0.002

HDL-C (mmol/L)

1.08 ± 1.01

1.11 ± 0.28

0.606

Lp(a) (mg/dL)

11.0 (7.0–16.0)

52.6 (37.0–80.0)

< 0.001

Triglyceride (mmol/L)

1.36 ± 0.79

1.33 ± 0.71

0.654

Medication use after discharge

Statins [cases (%)]

365 (100)

151 (100)

1

Ezetimibe [cases (%)]

27 (7.40)

7 (4.64)

0.25

Aspirin [cases (%)]

365 (100)

151 (100)

1

Clopidogrel [cases (%)]

285 (78.08)

118 (78.15)

0.987

Ticagrelor [cases (%)]

80 (21.92)

33 (21.85)

0.987

Medication use before the endpoints

Statins [cases (%)]

365 (100)

151 (100)

1

Ezetimibe [cases (%)]

22 (6.03)

7 (4.64)

0.532

Dual antiplatelet therapy [cases (%)]

30 (8.22)

19 (12.58)

0.124

Aspirin [cases (%)]

30 (8.22)

19 (12.58)

1

Clopidogrel [cases (%)]

21 (5.75)

15 (9.93)

0.489

Ticagrelor [cases (%)]

9 (2.47)

4 (2.65)

0.489

Single antiplatelet therapy [cases (%)]

335 (91.78)

132 (87.42)

0.124

Aspirin [cases (%)]

296 (81.10)

119 (78.81)

0.579

Clopidogrel [cases (%)]

39 (10.68)

13 (8.61)

0.579

Ticagrelor [cases (%)]

0

0

–